Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials

In two pivotal efficacy studies (ZOE-50; ZOE-70), the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster (HZ). Adults aged ≥50 or ≥70 years (ZOE-50 [NCT01165177]; ZOE-70 [NCT01165229]) were randomized to receive 2 doses of RZV or placebo 2 months apart. V...

Descripción completa

Detalles Bibliográficos
Autores principales: Oostvogels, Lidia, Heineman, Thomas C., Johnson, Robert W., Levin, Myron J., McElhaney, Janet E., Van den Steen, Peter, Zahaf, Toufik, Dagnew, Alemnew F., Chlibek, Roman, Diez-Domingo, Javier, Gorfinkel, Iris S., Hervé, Caroline, Hwang, Shinn-Jang, Ikematsu, Hideyuki, Kalema, George, Lal, Himal, McNeil, Shelly A., Mrkvan, Tomas, Pauksens, Karlis, Smetana, Jan, Watanabe, Daisuke, Weckx, Lily Yin, Cunningham, Anthony L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930113/
https://www.ncbi.nlm.nih.gov/pubmed/31216205
http://dx.doi.org/10.1080/21645515.2019.1627818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930113/
https://www.ncbi.nlm.nih.gov/pubmed/31216205
http://dx.doi.org/10.1080/21645515.2019.1627818

Ejemplares similares